Coronavirus: Unexpectedly, AstraZeneca Vaccine Phase 3 Trial Suspended
On September 8, British pharmaceutical company AstraZeneca announced that it had suspended the global phase III clinical trial of the COVID-19 vaccine AZD1222 (ChAdOx1) due to an UNEXPLAINED disease in a British volunteer.
As one of the companies with the fastest progress in the research and development of COVID-19 vaccines in the world, AstraZeneca has suspended clinical trials in the final sprint stage, which has attracted great attention from the market.